Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength

The Relative Strength (RS) Rating for Aurinia Pharmaceuticals climbed into a new percentile Tuesday, with a rise from 79 to 82. Last week it actually hit 83, then fell on a couple of down days before reversing higher.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.

Decades of market research reveals that the top-performing stocks tend to have an RS Rating of at least 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Aurinia Pharmaceuticals is still working on a consolidation with a 12.13 buy point. See if the stock can finally break out in heavy trade.

The company reported 0% earnings growth in its most recent report. Sales gains came in at 59%. The company is expected to report its latest earnings and sales numbers on or around Aug. 9.

Aurinia Pharmaceuticals holds the No. 20 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics and Vertex Pharmaceuticals are also among the group's highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.